$0.34
3.91%
Nasdaq, Apr 21, 07:48 pm CET
ISIN
IL0011814113
Symbol
PLRZ
Sector
Industry

Polyrizon Stock price

$0.36
-0.28 44.39% 1M
-1.19 77.04% 6M
-1.81 83.60% YTD
-1.19 77.04% 1Y
-1.19 77.04% 3Y
-1.19 77.04% 5Y
-1.19 77.04% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
-0.01 1.96%
ISIN
IL0011814113
Symbol
PLRZ
Sector
Industry

Key metrics

Market capitalization $1.56m
Enterprise Value $-990.00k
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.86
P/B ratio (TTM) P/B ratio 0.28
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-1.30m
Free Cash Flow (TTM) Free Cash Flow $-1.15m
EPS (TTM) EPS $-0.37

Is Polyrizon a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Financial data from Polyrizon

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.12 0.12
-
-
-0.12 -0.12
-
-
- Selling and Administrative Expenses 0.53 0.53
77% 77%
-
- Research and Development Expense 0.53 0.53
61% 61%
-
-1.18 -1.18
87% 87%
-
- Depreciation and Amortization 0.12 0.12
-
-
EBIT (Operating Income) EBIT -1.30 -1.30
105% 105%
-
Net Profit -1.55 -1.55
158% 158%
-

In millions USD.

Don't miss a Thing! We will send you all news about Polyrizon directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Polyrizon Stock News

Neutral
GlobeNewsWire
10 days ago
Raanana, Israel, April 11, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that on April 8, 2025, the Company received a written notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nas...
Neutral
GlobeNewsWire
19 days ago
Raanana, Israel, April 02, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ), a biotech company specializing in innovative intranasal hydrogels, today announced that it has entered into an agreement with a globally recognized branding and trademark consultancy firm, renowned for working with leading pharmaceutical and medical device companies worldwide.
Neutral
GlobeNewsWire
20 days ago
RAANANA, ISRAEL, April 01, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a biotech company specializing in innovative intranasal hydrogels, today announced the closing of its previously announce private placement  of approximately $17.0 million of Ordinary Shares and/or pre-funded and investor warrants at a price of $0.48 per Ordinary Unit.
More Polyrizon News

Company Profile

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Head office Israel
CEO Tomer Izraeli
Employees 6
Founded 2005
Website polyrizon-biotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today